clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Drug Eruptions D003875 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
al-Assi MT et al. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. 1994 Am. J. Gastroenterol. pmid:8053435
Guelar A et al. [Therapeutic alternatives for cases of cerebral toxoplasmosis in patients with AIDS: clarithromycin and atovaquone]. 1994 Enferm. Infecc. Microbiol. Clin. pmid:8011719
Aspin MM et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. 1994 J. Pediatr. pmid:8021763
Thijs JC et al. Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. 1994 Aliment. Pharmacol. Ther. pmid:8186339
Honeybourne D et al. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. 1994 Eur. Respir. J. pmid:7925906
Gad A and Unge P Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it. 1994 J. Clin. Gastroenterol. pmid:7930437
Morikawa K et al. Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro. 1994 Antimicrob. Agents Chemother. pmid:7532933
Goldman RC et al. Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. 1994 Antimicrob. Agents Chemother. pmid:7979278
Roblin PM et al. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. 1994 Antimicrob. Agents Chemother. pmid:7979292
Valero G et al. Activities of clarithromycin, ofloxacin, and clarithromycin plus ethambutol against Mycobacterium simiae in murine model of disseminated infection. 1994 Antimicrob. Agents Chemother. pmid:7872769
Yamada S et al. [A child with iritis due to Chlamydia pneumoniae infection]. 1994 Kansenshogaku Zasshi pmid:7876679
Tessier MH et al. Clarithromycin for atypical mycobacterial lymphadenitis in non-immunocompromised children. 1994 Dec 24-31 Lancet pmid:7997032
Mor N et al. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. 1994 Jan-Feb Pharmacotherapy pmid:8159593
Winter J Intravenous clarithromycin. 1994 Mar 16-Apr 5 Br J Hosp Med pmid:8032567
Gersema LM et al. Suspected drug interaction between cyclosporine and clarithromycin. 1994 Mar-Apr J. Heart Lung Transplant. pmid:8031821
Heifets LB Quantitative cultures and drug susceptibility testing of Mycobacterium avium clinical isolates before and during the antimicrobial therapy. 1994 Mar-Apr Res. Microbiol. pmid:7809471
Dautzenberg B Clinical trials in Mycobacterium avium therapy: lessons to take home. 1994 Mar-Apr Res. Microbiol. pmid:7809472
Scaglione F et al. Effect of antibiotics on Bordetella pertussis adhering activity: hypothesis regarding mechanism of action. 1994 May-Jun Chemotherapy pmid:7515782
O'Connor NK and Fris J Clarithromycin-carbamazepine interaction in a clinical setting. 1994 Nov-Dec J Am Board Fam Pract pmid:7847111
Cama VA et al. Treatment of acute and chronic Cryptosporidium parvum infections in mice using clarithromycin and 14-OH clarithromycin. 1994 Sep-Oct J. Eukaryot. Microbiol. pmid:7804227
Adamek RJ et al. Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. 1995 Am. J. Gastroenterol. pmid:7801936
FDA approves Biaxin for MAC prophylaxis. Food and Drug Administration. 1995 J Int Assoc Physicians AIDS Care pmid:11363096
Jaup BH and Norrby A Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7771426
Musher DM Clarithromycin therapy for Mycobacterium avium complex bacteremia. 1995 Ann. Intern. Med. pmid:7778830
van der Meer JT and Danner SA Clarithromycin therapy for Mycobacterium avium complex bacteremia. 1995 Ann. Intern. Med. pmid:7778831
Burette A and Glupczynski Y Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease. 1995 Infection pmid:7782116
Savarino V et al. Helicobacter pylori eradication and reinfection. 1995 Lancet pmid:7783564
Comley JC and Sterling AM Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. 1995 Antimicrob. Agents Chemother. pmid:7785975
Struillou L et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. 1995 Antimicrob. Agents Chemother. pmid:7785988
Fong IW et al. Clarithromycin versus cefaclor in lower respiratory tract infections. The Canadian Bronchitis Study Group. 1995 Clin Invest Med pmid:7788958
Goddard A and Logan R One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. 1995 Eur J Gastroenterol Hepatol pmid:7866804
Labenz J et al. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. 1995 Eur J Gastroenterol Hepatol pmid:7866820
Weits J and Sprenger HG [Surgical treatment of lymphadenitis caused by non-tuberculous mycobacteria in children]. 1995 Ned Tijdschr Geneeskd pmid:8524431
Nash KA and Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. 1995 Antimicrob. Agents Chemother. pmid:8592991
Ramírez Ramos A [Treatment of Helicobacter pylori infection: current status]. 1995 Rev Gastroenterol Peru pmid:8520021
Lee D et al. Localized Mycobacterium avium-intracellulare mastitis in an immunocompetent woman with silicone breast implants. 1995 Plast. Reconstr. Surg. pmid:7809228
Adamek RJ et al. [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection]. 1995 Dtsch. Med. Wochenschr. pmid:7889816
Midoneck SR and Etingin OR Clarithromycin-related toxic effects of digoxin. 1995 N. Engl. J. Med. pmid:7477159
Forslund T et al. Disseminated cutaneous infection due to Mycobacterium chelonae in a patient with rheumatoid arthritis, amyloidosis, and renal failure. 1995 Nephrol. Dial. Transplant. pmid:7478131
Cavalieri SJ et al. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:7492101
Englishby VL Case reports of death associated with pseudomembranous colitis and clarithromycin. 1995 Eur J Gastroenterol Hepatol pmid:7496875
Fabry W et al. Comparison of the E test and a proportion dilution method for susceptibility testing of Mycobacterium tuberculosis. 1995 Zentralbl. Bakteriol. pmid:9810662
Xu G et al. [Effect of clarithromycin on macrophage functions]. 1995 Kansenshogaku Zasshi pmid:7594777
Gelber RH et al. Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against M. leprae-infected mice. 1995 Int. J. Lepr. Other Mycobact. Dis. pmid:7602221
Milde P et al. Cutaneous bacillary angiomatosis in a patient with chronic lymphocytic leukemia. 1995 Arch Dermatol pmid:7543264
Nightingale SD et al. Clarithromycin-induced mania in two patients with AIDS. 1995 Clin. Infect. Dis. pmid:7548513
Matsiota-Bernard P et al. Mycobacterium genavense infection in a patient with AIDS who was successfully treated with clarithromycin. 1995 Clin. Infect. Dis. pmid:7548515
Citron DM et al. Activity of ampicillin/sulbactam, ticarcillin/clavulanate, clarithromycin, and eleven other antimicrobial agents against anaerobic bacteria isolated from infections in children. 1995 Clin. Infect. Dis. pmid:7548597
Ishii K et al. A new pharmacokinetic model including in vivo dissolution and gastrointestinal transit parameters. 1995 Biol. Pharm. Bull. pmid:7550125
Harris AW et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. 1995 Aliment. Pharmacol. Ther. pmid:7605863
Katelaris PH et al. A randomized prospective comparison of clarithromycin versus amoxycillin in combination with omeprazole for eradication of Helicobacter pylori. 1995 Aliment. Pharmacol. Ther. pmid:7605864
Yousfi MM et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. 1995 Aliment. Pharmacol. Ther. pmid:7605865
Chevalley GF et al. [Uveitis associated with rifabutin treatment. Apropos of 3 patients]. 1995 Klin Monbl Augenheilkd pmid:7609395
Blum AL et al. [Functional dyspepsia: approaches to Helicobacter pylori eradication therapy]. 1995 Leber Magen Darm pmid:7609589
Labenz J et al. [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. 1995 Leber Magen Darm pmid:7609590
Reppun JI From prontolyn to biaxin: the half-century of antibiotics. 1995 Hawaii Med J pmid:7628918
Chin DP and Hopewell PC How to treat bacteraemic Mycobacterium avium complex disease. 1995 Lancet pmid:7564723
Kuhn SM et al. Treatment of Mycobacterium marinum facial abscess using clarithromycin. 1995 Pediatr. Infect. Dis. J. pmid:7567299
Lacassin F et al. Clarithromycin-minocycline combination as salvage therapy for toxoplasmosis in patients infected with human immunodeficiency virus. 1995 Antimicrob. Agents Chemother. pmid:7695324
Labenz J and Börsch G Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7733070
Forné M et al. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. 1995 Am. J. Gastroenterol. pmid:7733075
Tebas P et al. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. 1995 Clin. Infect. Dis. pmid:7742453
Teare JP et al. Pseudomembranous colitis following clarithromycin therapy. 1995 Eur J Gastroenterol Hepatol pmid:7743311
Pollak PT et al. Delirium probably induced by clarithromycin in a patient receiving fluoxetine. 1995 Ann Pharmacother pmid:7655131
Ozmen MM and Johnson CD Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? 1995 Am. J. Gastroenterol. pmid:7661197
Savarino V et al. New insight in the mechanism of omeprazole antimicrobial combinations to eradicate Helicobacter pylori. 1995 Am. J. Gastroenterol. pmid:7717343
Saito H et al. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. 1995 Tuber. Lung Dis. pmid:7718848
Schütze K and Hentschel E Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. 1995 Z Gastroenterol pmid:8600661
Tseng AL and Walmsley SL Rifabutin-associated uveitis. 1995 Ann Pharmacother pmid:8573961
Moayyedi P et al. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574714
Fujioka T et al. Peptic ulcer recurrence after Helicobacter pylori eradication: a 5-year follow-up study. 1995 Eur J Gastroenterol Hepatol pmid:8574733
Deltenre M et al. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. 1995 Eur J Gastroenterol Hepatol pmid:8574734
Fukuda Y et al. Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574735
Graham DY Clarithromycin for treatment of Helicobacter pylori infections. 1995 Eur J Gastroenterol Hepatol pmid:8574737
Takimoto T et al. Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori. 1995 Eur J Gastroenterol Hepatol pmid:8574739
Uemura N et al. Effect of Helicobacter pylori eradication on the healing and recurrence of peptic ulcer: combination therapy with low-dose omeprazole and clarithromycin. 1995 Eur J Gastroenterol Hepatol pmid:8574740
Ishii K et al. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. 1995 Chem. Pharm. Bull. pmid:8575034
Diehl HG [One week triple therapy for eradication of Helicobacter pylori infection: simple and effective]. 1995 Leber Magen Darm pmid:8577220
Götz JM et al. Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori. 1995 Scand. J. Gastroenterol. Suppl. pmid:8578230
Pavlopoulou J et al. Randomized controlled study of clarithromycin versus cefaclor suspensions in the treatment of acute otitis media in children. 1995 J Chemother pmid:8904139
Nishi K et al. [Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome]. 1995 Nihon Kyobu Shikkan Gakkai Zasshi pmid:8821993
Piersimoni C et al. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. 1995 J. Antimicrob. Chemother. pmid:8830013
Labenz J et al. High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. 1995 Digestion pmid:7895926
Van Asselt GJ et al. Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. 1995 J. Med. Microbiol. pmid:7563004
Moorthy RS and Rao NA Atypical mycobacterial wound infection after blepharoplasty. 1995 Br J Ophthalmol pmid:7880802
Yoshizawa A et al. [Legionella pneumonia diagnosed by urinary antigen detection]. 1995 Nihon Kyobu Shikkan Gakkai Zasshi pmid:7791279
Lounis N et al. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. 1995 Antimicrob. Agents Chemother. pmid:7793860
Fattorini L et al. In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. 1995 Antimicrob. Agents Chemother. pmid:7793873
Abbott files SNDA for MAC prophylaxis. 1995 J Int Assoc Physicians AIDS Care pmid:11362606
Cohen Y et al. Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. 1995 Antimicrob. Agents Chemother. pmid:7793882
Pierce M Another perspective on MAC prophylaxis. Interview by Gordon Nary. 1995 J Int Assoc Physicians AIDS Care pmid:11362746
Furney SK et al. Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. 1995 Antimicrob. Agents Chemother. pmid:7793895
Archange YR et al. Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. 1995 J Int Assoc Physicians AIDS Care pmid:11362747
Brown BA et al. Clarithromycin-induced hepatotoxicity. 1995 Clin. Infect. Dis. pmid:7795060
Physician's aggressive preventive therapy differs. 1995 AIDS Alert pmid:11362774
Raffi F et al. Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. 1995 Clin. Infect. Dis. pmid:7795062
New drug applications sought. 1995 AIDS Alert pmid:11362777
Smart T Cryptosporidiosis at ICAAC. 1995 GMHC Treat Issues pmid:11362913
Sharma PK and Tami TA AIDS: lessons from the last decade and prospects for the future. 1995 Ear Nose Throat J pmid:7796740
Researchers find new drugs to fight MAC. 1995 AIDS Alert pmid:11362925